drugset / Trial / NCT02723877
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
Phase 1/2
Completed
41 enrolled
PIQUR Therapeutics AG
Barts Cancer Institute · collabChurchill Hospital · collabFundación Instituto Valenciano de Oncología · collabHospital Universitari Vall d'Hebron Research Institute · collabHospital Universitario Ramon y Cajal · collabInstitut Català d'Oncologia · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label,non randomized, multi-center, phase 1/2b (dose escalation followed by expansion part) study evaluating clinical safety, efficacy and pharmacokinetics of PQR309 in combination with standard dose of eribulin in patients with locally advanced or metastatic HER2-negative (escalation part) and Triple Negative Breast Cancer (expansion part).
Timeline
- Start
- 2016-03-28
- Primary completion
- 2018-10-03
- Completion
- 2018-10-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimiralisib | Small molecule | — | — |
| Background | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |